Results 271 to 280 of about 146,874 (392)

CLINICAL STUDY OF TREATMENT WITH TRASTUZUMAB FOR HER2 POSITIVE METASTATIC BREAST CANCER

, 2004
Masaya Nomura, Yoshifumi Inoue, Hiroshi Katsura, Shigeo Fujita, Jun Sakao, Hirohiko Yokotani, Yuichi Fumimoto, Yukinobu YOSHIKAWA, Shigeo Soda   +8 more
openalex   +2 more sources

The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma [PDF]

, 2005
Filippo Montemurro, Massimo Aglietta
openalex   +1 more source

Integrating genomic mutations and tumor-infiltrating lymphocytes improves prediction of response to trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer. [PDF]

Cancer Drug Resist
Lu S, Zhang Y, Tong Y, Shu L, Huang R, Gu Y, Wang C, Li J, Shen K, Dong L, Chen X.   +10 more
europepmc   +1 more source

Unveiling the impact of chemotherapy in patients with breast cancer: A longitudinal study on peripheral inflammation, multimodal magnetic resonance imaging, and cognition

Cancer, Volume 131, Issue 19, 1 October 2025.
Abstract Background The pathophysiology of chemotherapy‐induced cognitive impairment (CICI) remains unclear. Besides direct neurotoxicity, chemotherapy may trigger peripheral proinflammatory responses leading to neuroinflammation and neuronal injury.
Rob Colaes, Gwen Schroyen, Ahmed Radwan, Rebeca Alejandra Gavrila Laic, Shannon Helsper, Uwe Himmelreich, Sigrid Hatse, Ann Smeets, Karen Caeyenberghs, Stefan Sunaert, Sabine Deprez   +10 more
wiley   +1 more source

A CASE OF RECURRENT BREAST CANCER WITH BRAIN METASTASIS AFTER A COMPLETE RESPONSE TO TRASTUZUMAB-DOCETAXEL THERAPY

, 2004
Tsuyoshi Nakagawa, Takayuki Osanai, Yoko Oishi, Youichi Toriya, Tomoyuki Aruga, Kenichi Sugihara   +5 more
openalex   +2 more sources

Supraventricular Tachycardia in a Patient on Trastuzumab [PDF]

, 2005
Ritu Jain, C Bakhshi, P.S.R.K. Sastry, Anjana Sainani, SH Advani   +4 more
openalex   +1 more source

Pyrotinib versus pertuzumab with trastuzumab and taxane in HER2-positive metastatic breast cancer: a Chinese multicenter real-world study. [PDF]

Oncologist
Liu B, Yi Z, Tian C, Deng J, Feng R, Hu ZY, Xie N, Li Y, Zhao J, Wu T, Ouyang Q.   +10 more
europepmc   +1 more source

Association Between the Volume Transfer Constant (Ktrans) From Dynamic Contrast‐Enhanced Perfusion MR and HER2 Status in Breast Cancer Brain Metastases

Cancer Reports, Volume 8, Issue 10, October 2025.
ABSTRACT Background With the development of new human epidermal growth factor 2 (HER2)‐targeting therapies, a non‐invasive method of determining the HER2 status of breast cancer brain metastases can be of great clinical value, particularly given the risks of brain biopsy and the possibility of discordance between HER2 status of the primary breast ...
Jonathan R. Young, Luke N. Ledbetter, Julie A. Ressler, Mark S. Shiroishi, Joanne E. Mortimer, Daniel Schmolze, Mariko Fitzgibbons, Bihong T. Chen   +7 more
wiley   +1 more source

Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2. [PDF]

Mol Cancer Ther
Parakh S, Huynh N, Cao DD, Rigopoulos A, Gloria B, Burvenich IJG, Murone C, Wichmann CW, Guo NY, Senko C, Parslow A, Allan L, Osellame LD, Janes PW, Scott FE, Liu Z, Gan HK, Scott AM.   +17 more
europepmc   +1 more source

Disposition and Absolute Bioavailability of Oral Imlunestrant in Healthy Women: A Phase 1, Open‐Label Study

Clinical Pharmacology in Drug Development, Volume 14, Issue 10, Page 764-775, October 2025.
Abstract Imlunestrant (LY3484356) is a next‐generation orally bioavailable selective estrogen receptor degrader being investigated for the treatment of estrogen receptor–positive advanced breast and endometrial cancers. This Phase 1, open‐label, 2‐part study evaluated the disposition and absolute bioavailability of [14C]‐imlunestrant in 16 US‐based ...
Amita Datta‐Mannan, Boris Czeskis, Elaine Shanks, Eunice Yuen, Stephen Hall, Vivian Rodriguez Cruz, Kenneth Cassidy   +6 more
wiley   +1 more source